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BACKGROUND Reoperative procedure for the substitution of failed mitral bioprosthesis is a procedure that might involve considerable risk. In some special cases with selected risk factors, mortality is high and might even contraindicate the procedure. The minimally invasive valve-in-valve transcatheter transapical mitral valve implant offers an alternative, reducing morbidity and mortality. The objective of this paper is the evaluation of these implants using the Braile Inovare prosthesis.
METHODS
The transcatheter balloon-expandable Braile Inovare prosthesis was used in 12 cases, with an average EuroSCORE of 20.1%. Procedures were performed in a hybrid operative room, under fluoroscopic and echocardiographic control. Through left minithoracotomy, the prostheses were implanted through the cardiac apex, under rapid pacing. Seriated echocardiographic and clinical controls were performed. Follow-up varied from 1 to 30 months.
RESULTS Correct prosthesis release took place in all cases. In one case, there was need for right lateral thoracotomy for the release of an embolized prosthesis. There was no operative mortality. 30 day mortality was of one case (8.3%). Ejection fraction showed a significant improvement after the 7th post-operative day and the aortic gradient also showed a reduction. Residual mitral regurgitation was not present. There was no peripheral vascular complication or complete atrioventricular block.
CONCLUSIONS The mitral valve-in-valve transcatheter implant in failed bioprosthesis is a safe procedure, with low morbidity and mortality. This possibility might alter prosthesis selection in the initial surgical prosthesis selection, favoring bioprostheses. BACKGROUND Percutaneous mitral valve edge-to-edge repair using the MitraClip system has been widespread for significant mitral regurgitation (MR) patients with high surgical risk. Learning curve is an important concern for the institute which introduce the MitraClip procedure in the future. In this study, the effect of learning curve on the procedural results and recurrent MR was investigated.
METHODS From November 2005 to October 2013, 174 patients underwent the MitraClip procedure in our institute. These patients were classified into first 50 patients (period 1), second 50 patients (period 2), and the other 74 patients (period 3), and learning curve was evaluated by comparison of procedural results and the subsequent recurrence of MR between the 3 groups. All MitraClip procedures were performed by or under the supervision of a single operator (S. Kar).
RESULTS Fluoroscopic time was 45.1 AE 18.2 min in period 1, 42.7 AE 23.1 min in period 2, and 34.8 AE 13.8 min in period 3, and significantly decreased from period 1 to period 3 (p¼0.007). The number of clips was 1.38 AE 0.57 in period 1, 1.48 AE 0.51 in period 2, and 1.60 AE 0.52 in period 3 (p¼0.07). Although acute procedural success (residual MR </¼2þ immediately after the procedure) was similarly achieved in the 3 groups (94.0% vs. 94.0% vs. 98.6%, p¼0.31), the distribution of residual MR grade after the procedure was significantly better in period 3 than in period 1 (p¼0.04). Among patients with acute procedural success, recurrent MR within 1 year was observed more frequently in period 1 (38.3%) than in period 2 (10.6%, p¼0.002) and period 3 (15.3%, p¼0.004).
CONCLUSIONS Learning curve of the MitraClip procedure was observed in terms of procedural quality and device durability. When starting the MitraClip program, these findings should be considered. BACKGROUND Targeted transseptal (TS) puncture is an essential technique for many structural heart interventions. Spatial accuracy of standard versus radiofrequency (RF) needles has not previously been reported.
METHODS Consecutive patients undergoing left-sided structural heart interventions requiring TS puncture were included in an ongoing registry. The BRK needle (St Jude Med) paired with Mullins sheath (Medtronic) was used alternately with RF needle (Baylis Med) paired with SL1 Sheath (St Jude Med). Procedural times were: (1) withdrawing the TS system from the SVC and positioning at the intended TS site; (2) time to cross septum once site was selected; (3) time to advance the sheath across the septum. Transesophageal echocardiographic (TEE) measurements of intended versus final TS crossing site on the septum were obtained. These measurements were made from reproducible edges of the visible portions of the fossa ovalis and/or interatrial septum to the TS site in bicaval and short axis (SAX) TEE views both pre and post TS puncture. Pre puncture and maximal tenting of the septum were also quantified.
RESULTS 25 patients underwent standard needle and 27 RF needle TS access. 2 patients crossed over from the standard needle group to the RF group due to inability to puncture. Data is reported in an "as treated" analysis. Left-sided heart interventions included the MitraClip (N¼35), Watchman (N¼9), and Lariat (N¼7) procedures and percutaneous balloon mitral valvuloplasty (N¼1). The principal findings are shown in the Table. TS procedural times significantly favored the RF needle for time from septum to puncture. Both standard and RF access yielded accurate crossing technique with no statistical differences between the intended and actual crossing site. Maximal tenting was significantly less with the RF needle. Few patients had challenging atrial anatomy such as atrial septal aneurysm, thickened septum primum or prior TS attempts. 2 patients in the standard arm required the mandril wire for assistance to cross. There were no major complications. 
